IM Cannabis Reports Second Quarter 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 12 2025
0mins
Should l Buy IMCC?
Source: PRnewswire
Financial Performance Overview: IM Cannabis Corp. reported a 14% decrease in revenue for Q2 2025, totaling $12.7 million, primarily due to external challenges such as the ongoing war in Israel and supply chain delays. However, the company achieved a significant 306% increase in gross profit and improved its EBITDA from a loss of $2.3 million to a profit of $0.1 million.
Management Insights: CEO Oren Shuster emphasized the resilience of the company's long-term strategy despite current obstacles, while CFO Uri Birenberg highlighted disciplined cost management and operational efficiency as key factors contributing to their profitability and margin growth amidst declining revenues.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMCC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMCC
About IMCC
IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IM Cannabis Corp. Secures $2.17 Million in Debt Financing
- Financing Amount: IM Cannabis Corp. successfully raised $2.17 million through a third-party loan agreement to address liquidity needs, enhancing financial flexibility amid operational challenges.
- First Note Details: The first note issued amounts to $1.54 million with an 8% annual interest rate, increasing to 14% upon default, and has an 18-month maturity, reflecting the company's focus on effective debt management.
- Second Note Arrangement: The second note totals $632,911 with similar terms, including an 8% interest rate and identical repayment structure, further solidifying the company's financial foundation.
- Equity Conversion Rights: Both notes are convertible into common shares at a price of $1.47 or 90% of the lowest VWAP over 20 days, providing the company with a potential equity financing avenue.
See More
IM Cannabis Corp. Secures $2.17 Million in Debt Financing
- Financing Amount: IM Cannabis Corp. successfully raised $2.17 million through an agreement with a third-party lender to address liquidity needs, thereby enhancing financial flexibility.
- First Note Details: The company issued a first note of $1.54 million with an 8% annual interest rate, increasing to 14% upon default, and an 18-month maturity, reflecting a cautious approach to debt management.
- Second Note Issuance: The second note amounts to $632,911.50 with the same interest rate and maturity as the first, further solidifying the company's financial foundation to support operations and strategic initiatives.
- Equity Conversion Rights: Both notes are convertible into common shares, with the first note's conversion price set at $1.47 per share, ensuring the company maintains flexibility in future financing while providing potential value appreciation for investors.
See More
IM Cannabis Evaluates Strategic Entry into US Market Following Regulatory Changes
- Market Opportunity Assessment: IM Cannabis Corp. is evaluating strategic opportunities to enter the U.S. cannabis market in response to President Trump's December 18 executive order directing the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III, which is expected to open new revenue streams for the company.
- Advisory Services Collaboration: To advance its entry into the U.S. market, IM Cannabis has engaged SSC Advisors, who will provide customary financial advisory services, including strategic guidance on potential U.S. market entry and identifying prospective partners or acquirers, thereby enhancing the company's competitive positioning.
- Stock Price Reaction: In pre-market trading, IMCC shares rose by 9.42% to $1.51, reflecting investor optimism regarding the company's potential entry into the U.S. market, which may further drive the stock price upward.
- Strategic Significance: By entering the U.S. market, IM Cannabis can not only capitalize on the growing demand for medical cannabis but also enhance its brand influence and market share globally, aligning with the company's long-term growth strategy.
See More
IM Cannabis Corp Evaluates U.S. Market Expansion Opportunities
- Strategic Expansion: IM Cannabis Corp is actively evaluating strategic opportunities to enter the U.S. cannabis market, a move prompted by President Trump's executive order on December 18, 2025, aimed at expediting marijuana rescheduling, which is expected to unlock new growth potential for the company.
- Financial Advisor Engagement: The company has engaged SSC Advisors to provide strategic guidance for U.S. market entry and assess potential divestitures of its German and Israeli operations, aiming to optimize resource allocation and enhance market competitiveness.
- Market Monitoring: IM Cannabis will continue to monitor developments related to the executive order and the federal rescheduling process to ensure agility in responding to the rapidly changing market environment, thereby seizing potential business opportunities.
- Revenue Expectations: The company anticipates that its preliminary unaudited revenue estimate for its German operations in Q4 2025 will provide critical insights for future strategic decisions, further driving sustainable growth in its highest value markets.
See More
IM Cannabis Corp. Evaluates U.S. Market Expansion Opportunities
- Strategic Expansion Plan: IM Cannabis Corp. is actively evaluating strategic opportunities to enter the U.S. cannabis market, a move prompted by President Trump's executive order on December 18, 2025, aimed at expediting the rescheduling of marijuana, potentially unlocking new market opportunities.
- Financial Advisor Engagement: The company has engaged SSC Advisors to provide strategic guidance on U.S. market entry and assess potential divestitures of its German and Israeli operations, which is expected to optimize resource allocation and enhance competitive positioning.
- Commitment to Market Monitoring: IM Cannabis Corp. will continue to monitor developments related to the executive order and the federal rescheduling process to ensure compliance and seize opportunities in a rapidly changing market environment.
- International Business Integration: The company will maintain its operations in Israel and Germany through subsidiaries, leveraging years of proprietary data and patient insights to ensure sustainable growth and compliance as it expands into new markets.
See More
IM Cannabis Appoints Asi Levi as CFO to Enhance Financial Management
- Executive Change: IM Cannabis has appointed Asi Levi as the new Chief Financial Officer, replacing Uri Birenberg, with Levi bringing over 15 years of financial management experience, which is expected to enhance the company's financial planning and budgeting capabilities.
- Experienced Leader: Levi previously served as CFO for Water Ways Technologies and DekelOil CI, possessing extensive experience in fundraising and cash flow management, which will aid IM Cannabis in achieving compliance under international financial reporting standards.
- Market Focus: IM Cannabis concentrates on the two largest medical cannabis markets, Israel and Germany, and Levi's appointment is anticipated to facilitate sustainable and profitable growth in these high-value markets.
- Strategic Goals: The company aims to amplify its commercial and brand power through a data-driven approach and a global supply chain, and Levi's addition is expected to further propel the achievement of these strategic objectives.
See More
IM Cannabis Corp. Secures $2.17 Million in Debt Financing
- Financing Amount: IM Cannabis Corp. successfully raised $2.17 million through a third-party loan agreement to address liquidity needs, enhancing financial flexibility amid operational challenges.
- First Note Details: The first note issued amounts to $1.54 million with an 8% annual interest rate, increasing to 14% upon default, and has an 18-month maturity, reflecting the company's focus on effective debt management.
- Second Note Arrangement: The second note totals $632,911 with similar terms, including an 8% interest rate and identical repayment structure, further solidifying the company's financial foundation.
- Equity Conversion Rights: Both notes are convertible into common shares at a price of $1.47 or 90% of the lowest VWAP over 20 days, providing the company with a potential equity financing avenue.
See More
IM Cannabis Corp. Secures $2.17 Million in Debt Financing
- Financing Amount: IM Cannabis Corp. successfully raised $2.17 million through an agreement with a third-party lender to address liquidity needs, thereby enhancing financial flexibility.
- First Note Details: The company issued a first note of $1.54 million with an 8% annual interest rate, increasing to 14% upon default, and an 18-month maturity, reflecting a cautious approach to debt management.
- Second Note Issuance: The second note amounts to $632,911.50 with the same interest rate and maturity as the first, further solidifying the company's financial foundation to support operations and strategic initiatives.
- Equity Conversion Rights: Both notes are convertible into common shares, with the first note's conversion price set at $1.47 per share, ensuring the company maintains flexibility in future financing while providing potential value appreciation for investors.
See More
IM Cannabis Evaluates Strategic Entry into US Market Following Regulatory Changes
- Market Opportunity Assessment: IM Cannabis Corp. is evaluating strategic opportunities to enter the U.S. cannabis market in response to President Trump's December 18 executive order directing the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III, which is expected to open new revenue streams for the company.
- Advisory Services Collaboration: To advance its entry into the U.S. market, IM Cannabis has engaged SSC Advisors, who will provide customary financial advisory services, including strategic guidance on potential U.S. market entry and identifying prospective partners or acquirers, thereby enhancing the company's competitive positioning.
- Stock Price Reaction: In pre-market trading, IMCC shares rose by 9.42% to $1.51, reflecting investor optimism regarding the company's potential entry into the U.S. market, which may further drive the stock price upward.
- Strategic Significance: By entering the U.S. market, IM Cannabis can not only capitalize on the growing demand for medical cannabis but also enhance its brand influence and market share globally, aligning with the company's long-term growth strategy.
See More
IM Cannabis Corp Evaluates U.S. Market Expansion Opportunities
- Strategic Expansion: IM Cannabis Corp is actively evaluating strategic opportunities to enter the U.S. cannabis market, a move prompted by President Trump's executive order on December 18, 2025, aimed at expediting marijuana rescheduling, which is expected to unlock new growth potential for the company.
- Financial Advisor Engagement: The company has engaged SSC Advisors to provide strategic guidance for U.S. market entry and assess potential divestitures of its German and Israeli operations, aiming to optimize resource allocation and enhance market competitiveness.
- Market Monitoring: IM Cannabis will continue to monitor developments related to the executive order and the federal rescheduling process to ensure agility in responding to the rapidly changing market environment, thereby seizing potential business opportunities.
- Revenue Expectations: The company anticipates that its preliminary unaudited revenue estimate for its German operations in Q4 2025 will provide critical insights for future strategic decisions, further driving sustainable growth in its highest value markets.
See More
IM Cannabis Corp. Evaluates U.S. Market Expansion Opportunities
- Strategic Expansion Plan: IM Cannabis Corp. is actively evaluating strategic opportunities to enter the U.S. cannabis market, a move prompted by President Trump's executive order on December 18, 2025, aimed at expediting the rescheduling of marijuana, potentially unlocking new market opportunities.
- Financial Advisor Engagement: The company has engaged SSC Advisors to provide strategic guidance on U.S. market entry and assess potential divestitures of its German and Israeli operations, which is expected to optimize resource allocation and enhance competitive positioning.
- Commitment to Market Monitoring: IM Cannabis Corp. will continue to monitor developments related to the executive order and the federal rescheduling process to ensure compliance and seize opportunities in a rapidly changing market environment.
- International Business Integration: The company will maintain its operations in Israel and Germany through subsidiaries, leveraging years of proprietary data and patient insights to ensure sustainable growth and compliance as it expands into new markets.
See More
IM Cannabis Appoints Asi Levi as CFO to Enhance Financial Management
- Executive Change: IM Cannabis has appointed Asi Levi as the new Chief Financial Officer, replacing Uri Birenberg, with Levi bringing over 15 years of financial management experience, which is expected to enhance the company's financial planning and budgeting capabilities.
- Experienced Leader: Levi previously served as CFO for Water Ways Technologies and DekelOil CI, possessing extensive experience in fundraising and cash flow management, which will aid IM Cannabis in achieving compliance under international financial reporting standards.
- Market Focus: IM Cannabis concentrates on the two largest medical cannabis markets, Israel and Germany, and Levi's appointment is anticipated to facilitate sustainable and profitable growth in these high-value markets.
- Strategic Goals: The company aims to amplify its commercial and brand power through a data-driven approach and a global supply chain, and Levi's addition is expected to further propel the achievement of these strategic objectives.
See More
